Skip to main content
Log in

Akute Herzinsuffizienz und kardiogener Schock

Ein Update

Acute heart failure and cardiogenic shock

An update

  • Schwerpunkt
  • Published:
Herz Aims and scope Submit manuscript

Zusammenfassung

Die akute Herzinsuffizienz beschreibt ein klinisches Syndrom, das sich aus einer systemischen Kongestion und erhöhten intrakardialen Füllungsdrücken ergibt. Prinzipiell kann es sich um eine Erstdiagnose handeln (De-novo-Herzinsuffizienz) oder um eine akute Verschlechterung einer vorbestehenden links- oder rechtsventrikulären Dysfunktion. Das Patientenkollektiv ist insgesamt sehr inhomogen, und folglich besteht auch eine deutliche Heterogenität bezüglich der zugrunde liegenden kardialen Pathologie, welche zur akuten Präsentation führt. Letztlich führt eine Dysfunktion des Ventrikels zur erhöhten Vor- und Nachlast mit resultierender retrograder Stauung und Minderdurchblutung. Aufgrund des Vorwärtsversagens (Hypoperfusion) und der systemischen Kongestion (Rückwärtsversagen) kann es zu einer Beeinträchtigung der Endorganfunktion kommen, was in seiner Maximalform dem kardiogenen Schock entspricht, bei dem eine ausreichende Organ- und Gewebeperfusion nicht mehr gewährleistet ist. Gegenwärtig konzentrieren sich die therapeutischen Ansätze vornehmlich auf die Behebung der zugrunde liegenden kardialen Dysfunktion, der Reduktion der Volumenüberladung (Dekongestion) und der hämodynamischen Stabilisierung mit kreislaufunterstützenden Medikamenten im Falle eines Hypoperfusionssyndroms. Trotz zahlreicher neuer therapeutischer Ansätze innerhalb der letzten Jahrzehnte ist die empirische Studienlage aktuell deutlich weniger breit als für die chronische Herzinsuffizienz, was sich auch in der nach wie vor hohen Einjahresletalität von etwa 20–30 % ausdrückt.

Abstract

Acute heart failure is a clinical syndrome resulting from elevated intracardiac filling pressures and a systemic venous congestion. In general, patients can present acutely without a history of structural cardiac disease (de novo heart failure) or with acute worsening of a pre-existing dysfunction of the right or left ventricle. The patient population is overall very inhomogeneous and as a result there is also a distinct heterogeneity with respect to the underlying cardiac pathology that leads to the acute presentation. Ultimately, ventricular dysfunction leads to increased preload and afterload resulting in decreased perfusion and retrograde congestion. The forward failure (hypoperfusion) and backwards failure (systemic congestion) can lead to impaired end organ function or even organ failure resulting in cardiogenic shock, in which sufficient organ and tissue perfusion is no longer possible. Consequently, therapeutic strategies currently focus on rectification of the underlying cardiac dysfunction, reduction of volume overload (decongestion) and hemodynamic stabilization with drugs supporting the circulation in the case of a hypoperfusion syndrome. Despite numerous new therapeutic strategies within the last two decades, the empirical data based on randomized trials is considerably less solid than in chronic heart failure, which is expressed in the almost unchanged 1‑year mortality of approximately 20–30%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726

    Article  CAS  PubMed  Google Scholar 

  2. Sinnenberg L, Givertz MM (2020) Acute heart failure. Trends Cardiovasc Med 30(2):104–112

    Article  PubMed  Google Scholar 

  3. Kurmani S, Squire I (2017) Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep 14(5):385–392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Nieminen MS, Brutsaert D, Dickstein K et al (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27(22):2725–2736

    Article  PubMed  Google Scholar 

  5. Nohria A, Tsang SW, Fang JC et al (2003) Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41(10):1797–1804

    Article  PubMed  Google Scholar 

  6. Platz E, Jhund PS, Claggett BL et al (2018) Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. Eur J Heart Fail 20(2):295–303

    Article  PubMed  Google Scholar 

  7. Mullens W, Damman K, Harjola VP et al (2019) The use of diuretics in heart failure with congestion—A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137–155

    Article  PubMed  Google Scholar 

  8. Rahman R, Paz P, Elmassry M et al (2021) Diuretic resistance in heart failure. Cardiol Rev 29(2):73–81

    Article  PubMed  Google Scholar 

  9. Freund Y, Cachanado M, Delannoy Q et al (2020) Effect of an emergency department care bundle on 30-day hospital discharge and survival among elderly patients with acute heart failure: the ELISABETH randomized clinical trial. JAMA 324(19):1948–1956

    Article  PubMed  Google Scholar 

  10. Kozhuharov N, Goudev A, Flores D et al (2019) Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA 322(23):2292–2302

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bistola V, Arfaras-Melainis A, Polyzogopoulou E et al (2019) Inotropes in acute heart failure: From guidelines to practical use: therapeutic options and clinical practice. Card Fail Rev 5(3):133–139

    Article  PubMed  PubMed Central  Google Scholar 

  12. Overgaard CB, Dzavik V (2008) Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 118(10):1047–1056

    Article  PubMed  Google Scholar 

  13. Gao F, Zhang Y (2021) Inotrope use and intensive care unit mortality in patients with cardiogenic shock: an analysis of a large electronic intensive care unit database. Front Cardiovasc Med 8:696138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cuffe MS, Califf RM, Adams KF et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287(12):1541–1547

    Article  CAS  PubMed  Google Scholar 

  15. Packer M, Colucci W, Fisher L et al (2013) Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 1(2):103–111

    Article  PubMed  Google Scholar 

  16. Mebazaa A, Nieminen MS, Packer M et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297(17):1883–1891

    Article  CAS  PubMed  Google Scholar 

  17. Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology 96(3–4):132–143

    Article  CAS  PubMed  Google Scholar 

  18. Mentz RJ, Hasselblad V, DeVore AD et al (2016) Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial). Am J Cardiol 117(3):404–411

    Article  CAS  PubMed  Google Scholar 

  19. Mentz RJ, Velazquez EJ, Metra M et al (2015) Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiol 11(5):585–595

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chen HH, Anstrom KJ, Givertz MM et al (2013) Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310(23):2533–2543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gottlieb SS, Stebbins A, Voors AA et al (2013) Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). J Am Coll Cardiol 62(13):1177–1183

    Article  CAS  PubMed  Google Scholar 

  22. Channer KS, McLean KA, Lawson-Matthew P, Richardson M (1994) Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 71(2):146–150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mullens W, Dauw J, Martens P et al (2022) Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 387(13):1185–1195

    Article  CAS  PubMed  Google Scholar 

  24. Schulze PC, Bogoviku J, Westphal J et al (2022) Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 146(4):289–298

    Article  CAS  PubMed  Google Scholar 

  25. Voors AA, Angermann CE, Teerlink JR et al (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 28(3):568–574

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Greene SJ, Fonarow GC, Vaduganathan M et al (2015) The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 12(4):220–229

    Article  PubMed  Google Scholar 

  27. Greene SJ, Triana TS, Ionescu-Ittu R et al (2020) In-hospital therapy for heart failure with reduced ejection fraction in the United States. JACC Heart Fail 8(11):943–953

    Article  PubMed  Google Scholar 

  28. Wirtz HS, Sheer R, Honarpour N et al (2020) Real-world analysis of guideline-based therapy after hospitalization for heart failure. J Am Heart Assoc 9(16):e15042

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shaefi S, O’Gara B, Kociol RD et al (2015) Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc 4(1):e1462

    Article  PubMed  PubMed Central  Google Scholar 

  30. Hochman JS, Sleeper LA, Webb JG et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341(9):625–634

    Article  CAS  PubMed  Google Scholar 

  31. Goldberg RJ, Spencer FA, Gore JM et al (2009) Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 119(9):1211–1219

    Article  PubMed  PubMed Central  Google Scholar 

  32. Aissaoui N, Puymirat E, Simon T et al (2014) Long-term outcome in early survivors of cardiogenic shock at the acute stage of myocardial infarction: a landmark analysis from the French registry of Acute ST-elevation and non-ST-elevation myocardial Infarction (FAST-MI) registry. Crit Care 18(5):516

    Article  PubMed  PubMed Central  Google Scholar 

  33. Combes A, Price S, Slutsky AS, Brodie D (2020) Temporary circulatory support for cardiogenic shock. Lancet 396(10245):199–212

    Article  PubMed  Google Scholar 

  34. Moustafa A, Khan MS, Saad M et al (2022) Impella support versus intra-aortic balloon pump in acute myocardial infarction complicated by cardiogenic shock: a meta-analysis. Cardiovasc Revasc Med 34:25–31

    Article  PubMed  Google Scholar 

  35. Thiele H, Zeymer U, Neumann FJ et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367(14):1287–1296

    Article  CAS  PubMed  Google Scholar 

  36. Udesen NJ, Moller JE, Lindholm MG et al (2019) Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J 214:60–68

    Article  PubMed  Google Scholar 

  37. Ostadal P, Rokyta R, Karasek J et al (2022) Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: Results of the ECMO-CS randomized clinical trial. Circulation. https://doi.org/10.1161/circulationaha.122.062949

    Article  PubMed  PubMed Central  Google Scholar 

  38. Thiele H, Freund A, Gimenez MR et al (2021) Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock—Design and rationale of the ECLS-SHOCK trial. Am Heart J 234:1–11

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul Christian Schulze.

Ethics declarations

Interessenkonflikt

J.G. Westphal und P.C. Schulze geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Westphal, J.G., Schulze, P.C. Akute Herzinsuffizienz und kardiogener Schock. Herz 48, 95–100 (2023). https://doi.org/10.1007/s00059-022-05159-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-022-05159-x

Schlüsselwörter

Keywords

Navigation